Cargando…

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

INTRODUCTION: Sotrovimab, a recombinant human monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had US Food and Drug Administration Emergency Use Authorization for the treatment of high-risk outpatients with mild-to-moderate coronavirus disease 2019 (COVI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Mindy M., Reyes, Carolina, Satram, Sacha, Birch, Helen, Gibbons, Daniel C., Drysdale, Myriam, Bell, Christopher F., Suyundikov, Anvar, Ding, Xiao, Maher, M. Cyrus, Yeh, Wendy, Telenti, Amalio, Corey, Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832411/ https://www.ncbi.nlm.nih.gov/pubmed/36629998 http://dx.doi.org/10.1007/s40121-022-00755-0

Ejemplares similares

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022)

510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
por: Bell, Christopher F, et al.
Publicado: (2023)

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
por: Satram, Sacha, et al.
Publicado: (2023)

CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)
por: Bell, C., et al.
Publicado: (2023)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab
por: Passariello, Margherita, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
por: Rockett, Rebecca, et al.
Publicado: (2022)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

An Analysis of COVID-19 Mortality During the Dominancy of Alpha, Delta, and Omicron in the USA
por: Tabatabai, Mohammad, et al.
Publicado: (2023)

512. Interim Results of a Prospective Cohort Study to Monitor the Emergence of Resistance in Immunocompromised Non-Hospitalized Patients With COVID-19 Who Were Treated with Sotrovimab in Great Britain: LUNAR Study 
por: Breuer, Judith, et al.
Publicado: (2023)

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
por: Mader, Anna-Lena, et al.
Publicado: (2022)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

2298. Penetration of SARS-CoV-2 Alpha, Delta, and Omicron Variants in the USA
por: Choi, Hosoon, et al.
Publicado: (2023)

LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
por: Tuan, Jessica, et al.
Publicado: (2022)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

(583) Sotrovimab in Heart Transplant Recipients with Covid-19 in the Omicron Era: A National Transplant Center Experience
por: Garcia, C.N. Perez, et al.
Publicado: (2023)

SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
por: Keyel, Alexander C., et al.
Publicado: (2022)

Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
por: Mambelli, Emanuele, et al.
Publicado: (2022)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
por: Kreye, Jakob, et al.
Publicado: (2023)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
por: Fujimoto, Kana, et al.
Publicado: (2022)

A comparison of multiple testing adjustment methods with block-correlation positively-dependent tests
por: Stevens, John R., et al.
Publicado: (2017)

Clinical use of pharmacogenomics
por: Telenti, Amalio
Publicado: (2012)

HIV-1 host interactions: integration of large-scale datasets
por: Telenti, Amalio
Publicado: (2009)

Host genome influences on susceptibility to HIV-1
por: Telenti, Amalio
Publicado: (2009)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Use of sotrovimab in vaccinated versus unvaccinated COVID‐19 patients in a resource‐limited emergency department during the omicron surge
por: Nene, Rahul V., et al.
Publicado: (2023)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
por: Woo, Marcel S., et al.
Publicado: (2022)

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS
por: Adachi, Eisuke, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
por: Hérate, Cécile, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d1b4oo1e06732p3ahraln38g4c